Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every launch, funding round, exec hire, and M&A move on Travere Therapeutics and CSL Vifor — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

Travere Therapeutics and CSL Vifor Launch FILSPARI for IgA Nephropathy Treatment in Switzerland

Oct 17, 2024•over 1 year ago
SwitzerlandBiotechnologyPharmaceutical

Product Description

Travere Therapeutics and CSL Vifor have announced that FILSPARI has received temporary marketing authorization from Swissmedic for the treatment of adults with primary IgA nephropathy, offering a once daily, oral treatment option for patients in Switzerland.

Company Information

Company

Travere Therapeutics and CSL Vifor

Location

Switzerland

About

Travere Therapeutics, Inc. and CSL Vifor are pharmaceutical companies collaborating to gain market approval for FILSPARI® (sparsentan) for the treatment of IgA Nephropathy.

Predictive Intelligence
Strategic

ML-powered predictions for Travere Therapeutics and CSL Vifor's next move

Learn about Strategic plan

Product Launch Insights

Based on market data
Market expansion signals
New product launches often coincide with market expansion initiatives